Skip to main content
SpringerLink
Log in

Management of cancer anorexia/cachexia

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Cancer anorexia/cachexia is a common clinical problem that substantially impacts upon the quality of life and survival of affected patients. Extensive investigations have not supported the use of either enteral or paternal hyperalimentation for such patients. Despite positive pilot trial reports, large randomized studies have been unable to demonstrate a clinically defensible role for either pentoxifylline, cyproheptadine, or hydrazine sulfate for patients with anorexia. Multiple placebo-controlled, randomized, double-blind, clinical trials have demonstrated that corticosteroids do have appetite-enhancing properties in patients suffering from cancer anorexia/cachexia, but none of these studies has demonstrated weight gain. In comparison, multiple studies have demonstrated that the progestational agent, megestrol acetate, has both appetite-enhancing and weight-promoting properties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bruera E (1992) Current pharmacological management of anorexia in cancer patients. Oncology 6:125–130

    Google Scholar 

  2. Bruera E, Roca E, Cedaro L, et al (1985) Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 69:751–754

    Google Scholar 

  3. Bruera E, Macmillan K, Kuehn N, et al (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66: 1279–1282

    Google Scholar 

  4. Chlebowski RT, Heber D, Richardson B, et al (1984) Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. Cancer Res 44:857–861

    Google Scholar 

  5. Chlebowski RT, Herrold J, Ali I, Oktay E, Chlebowski JS, et al (1986) Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. Cancer 58:183–186

    Google Scholar 

  6. Chlebowski RT, Bulcavage L, Grosvenor M, et al (1987) Hydrazine sulfate in cancer patients with weight loss. Cancer 59:406–410

    Google Scholar 

  7. Chlebowski RT, Bulcavage L, Grosvenor M, et al (1990) Hydrazine sulfate influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol 8:9–15

    Google Scholar 

  8. DeWys WB, Begg C, Lavin PT, et al (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 69:491–497

    Google Scholar 

  9. Dezube BJ, Fridovbich-Keil JL, Bouvard I, Lange RF, Pardee AB (1990) Pentoxifylline and wellbeing in patients with cancer. Lancet I 335:662

    Google Scholar 

  10. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 77:1653–1656

    Google Scholar 

  11. Feliu J, Gonzalez-Baron M, Berrocal A, et al (1991) Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? J Natl Cancer Inst 83:449

    Google Scholar 

  12. Filov VA, Danova LA, Gershanovich ML, et al (1990) Results of clinical evaluation of hydrazine sulfate. Vopr Onkol 36:721–726

    Google Scholar 

  13. Freed DJ, Banks AJ, Longson D, Burley DM (1975) Anabolic steroids in athletics: crossover double-blind trial on weightlifters. Br Med J 5:471–473

    Google Scholar 

  14. Gold J (1975) Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology 32:1–10

    Google Scholar 

  15. Goldberg RM, Loprinzi CL, Mailliard J, O'Fallon JR (1994) A randomized, placebo-controlled evaluation of pentoxifylline in patients with cancer anorexia and cachexia. A North Central Cancer Treatment Group Study. Proc Am Soc Clin Oncol 13:459

    Google Scholar 

  16. Kardinal CG, Loprinzi CL, Schaid DJ, et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662

    Google Scholar 

  17. Klein S, Simes J, Blockburn G (1986) Total parenteral nutrition and cancer clinical trials. Cancer 58:1378–1386

    Google Scholar 

  18. Kosty M, Fleishman S, Herndon J, Coughlin K, et al (1992) Cisplatin, vinblastine and hydrazine sulfate (NSC #150014) in advanced nonsmall lung cancer (NSCLC): a randomized, placebo-controlled, doubleblind phase III study. Proc Am Soc Clin Oncol 11:294

    Google Scholar 

  19. Lamb DR (1984) Anabolic steroids in athletics: how well do they work and how dangerous are they? Am J Sports Med 12:31–38

    Google Scholar 

  20. Lelli G, Angelelli B, Giambiasi ME, et al (1983) The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 6:561–568

    Google Scholar 

  21. Loprinzi CL, Ellison NM (1991) Treatment of cancer anorexia with megestrol acetate: which is the optimal dose? J Natl Cancer Inst 83:450

    Google Scholar 

  22. Loprinzi CL, Ellison NM, Schaid DJ, et al (1990) Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 82:1127–1132

    Google Scholar 

  23. Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ (1992) The effect of megestrol acetate on the human pituityadrenal axis. Mayo Clin Proc 67:1160–1162

    Google Scholar 

  24. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD (1992) Body composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 11:152–154

    Google Scholar 

  25. Loprinzi C, Johnson P, Jensen M (1992) Megestrol acetate for anorexia and cachexia. Oncology 49 [Suppl 2]:46–49

    Google Scholar 

  26. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LH, Goldberg RM, Tschetter LK, Hatfield AK, Morton RF (1993) Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 11:762–767

    Google Scholar 

  27. Loprinzi CL, Kuross SA, O'Fallon JR, Gesme DH, Gerstner JB, Rospond RM, Cobau CD, Goldberg RM (1994) Randomized, placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 12:1121–1125

    Google Scholar 

  28. Loprinzi CL, Goldberg RG, Su JQ, Mailliard J, Maksymiuk A, Kugler J, Jett J, Ghosh C, Pfeifle D, Wender D, Burch P (1994) Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol 12:1126–1129

    Google Scholar 

  29. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG (1974) Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 33:1607–1609

    Google Scholar 

  30. Nixon DW (1986) The value of parenteral nutritional support. Cancer 58:1902–1903

    Google Scholar 

  31. Ota DM, Copeland MD, Strobel HE, et al (1977) The effect of protein nutrition on host and tumor metabolism. J Surg Res 22:181–188

    Google Scholar 

  32. Piantadosi S (1990) Hazards of small clinical trials. J Clin Oncol 8:1–3

    Google Scholar 

  33. Popiela T, Lucchi R, Giongo F (1989) Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 25:1823–1829

    Google Scholar 

  34. Popp MD, Wagner SC, Brito OJ (1983) Host and tumor responses to increasing levels of intravenous nutritional support. Surgery 94:300–308

    Google Scholar 

  35. Popp MD, Kirkemo AK, Morrison SD, Brennen MF (1984) Tumor and host carcass changes during total parenteral nutrition in an anorectic rattumor system. Ann Surg 199:205–210

    Google Scholar 

  36. Slevin ML, Joel SP, Stubbs L, et al (1988) A randomized double-blind placebo-controlled trial of medroxyprogesterone acetate (MPA) in cancer cachexia. Proc Am Soc Clin Oncol 7:238

    Google Scholar 

  37. Steiger E, Oram-Smith J, Miller E, Kuol, Vars HM (1975) Effect of nutrition on tumor growth and tolerance of chemotherapy J Surg Res 18:455–461

    Google Scholar 

  38. Tahmindjis AJ (1976) The use of anabolic steroids by athletes to increase body weight and strength. Med J Aust 1:991–993

    Google Scholar 

  39. Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J (1992) Megestrol acetate in cancer anorexia and weight loss. Cancer 69:1268–1274

    Google Scholar 

  40. Warren S (1932) The immediate cause of death in cancer. Am J Med Sci 184:610–615

    Google Scholar 

  41. Wilcox J, Corr J, Shaw J, et al (1984) Prednisolone as an appetite stimulant in patients with cancer. Br Med J 288:27

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 55905, Rochester, MN, USA

    Charles L. Loprinzi M.D.

Authors
  1. Charles L. Loprinzi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Loprinzi, C.L. Management of cancer anorexia/cachexia. Support Care Cancer 3, 120–122 (1995). https://doi.org/10.1007/BF00365851

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00365851

Key words

Search

Navigation